These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 17225280)

  • 21. Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor.
    Poveda E; Rodés B; Toro C; Martín-Carbonero L; Gonzalez-Lahoz J; Soriano V
    AIDS; 2002 Sep; 16(14):1959-61. PubMed ID: 12351957
    [No Abstract]   [Full Text] [Related]  

  • 22. Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.
    De Castro N; Braun J; Charreau I; Pialoux G; Cotte L; Katlama C; Raffi F; Weiss L; Meynard JL; Yazdanpanah Y; Delaugerre C; Madelaine-Chambrin I; Aboulker JP; Molina JM;
    Clin Infect Dis; 2009 Oct; 49(8):1259-67. PubMed ID: 19757993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. T-20 salvage results hold up at 48 weeks.
    Feinberg J
    AIDS Clin Care; 2003 Sep; 15(9):77-8. PubMed ID: 14666913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical perspective of fusion inhibitors for treatment of HIV.
    Rockstroh JK; Mauss S
    J Antimicrob Chemother; 2004 May; 53(5):700-2. PubMed ID: 15044424
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Three new drugs approved by FDA.
    Hoyt G
    Surviv News (Atlanta Ga); 2003; ():13, 20. PubMed ID: 14696579
    [No Abstract]   [Full Text] [Related]  

  • 26. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.
    Kilby JM; Lalezari JP; Eron JJ; Carlson M; Cohen C; Arduino RC; Goodgame JC; Gallant JE; Volberding P; Murphy RL; Valentine F; Saag MS; Nelson EL; Sista PR; Dusek A
    AIDS Res Hum Retroviruses; 2002 Jul; 18(10):685-93. PubMed ID: 12167274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Looking within.
    Sahm J
    Res Initiat Treat Action; 2005; 11(2):5-6. PubMed ID: 16456973
    [No Abstract]   [Full Text] [Related]  

  • 28. T-20: a model for novel anti-HIV drugs in development.
    Laurence J
    AIDS Read; 2002 Nov; 12(11):469-70. PubMed ID: 12494906
    [No Abstract]   [Full Text] [Related]  

  • 29. Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies.
    Negredo E; Bonjoch A; Paredes R; Puig J; Clotet B
    Clin Infect Dis; 2005 Sep; 41(6):901-5. PubMed ID: 16107993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enfuvirtide (T-20): a novel human immunodeficiency virus type 1 fusion inhibitor.
    Cervia JS; Smith MA
    Clin Infect Dis; 2003 Oct; 37(8):1102-6. PubMed ID: 14523775
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Fusion inhibitor enfuvirtidE. Continuous virologic and immunologic response].
    Schäfer B
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():31. PubMed ID: 16385869
    [No Abstract]   [Full Text] [Related]  

  • 32. Enfuvirtide beneficial in experienced patients.
    AIDS Patient Care STDS; 2004 Jan; 18(1):57. PubMed ID: 15080095
    [No Abstract]   [Full Text] [Related]  

  • 33. Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV.
    Eron JJ; Gulick RM; Bartlett JA; Merigan T; Arduino R; Kilby JM; Yangco B; Diers A; Drobnes C; DeMasi R; Greenberg M; Melby T; Raskino C; Rusnak P; Zhang Y; Spence R; Miralles GD
    J Infect Dis; 2004 Mar; 189(6):1075-83. PubMed ID: 14999611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunologic benefits of enfuvirtide in patients enrolled in a drug assistance program.
    Saberi P; Caswell NH; Gruta CI; Tokumoto JN; Dong BJ
    Ann Pharmacother; 2008 May; 42(5):621-6. PubMed ID: 18413688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enfuvirtide, an HIV-1 fusion inhibitor.
    Jenny-Avital ER
    N Engl J Med; 2003 Oct; 349(18):1770-1; author reply 1770-1. PubMed ID: 14593994
    [No Abstract]   [Full Text] [Related]  

  • 36. A T-20 diary.
    Gormley F
    GMHC Treat Issues; 2002 Mar; 16(3):6-7. PubMed ID: 12004799
    [No Abstract]   [Full Text] [Related]  

  • 37. T-20 being called "miraculous".
    AIDS Patient Care STDS; 2002 Sep; 16(9):462. PubMed ID: 12412581
    [No Abstract]   [Full Text] [Related]  

  • 38. New-Fill on "hold" and open-label for T-20.
    Berger DS
    Posit Aware; 2002; 13(1):64-5. PubMed ID: 12216532
    [No Abstract]   [Full Text] [Related]  

  • 39. Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). T-1249 for T-20 salvage.
    Feinberg J
    AIDS Clin Care; 2003 Nov; 15(11):95-6. PubMed ID: 14682275
    [No Abstract]   [Full Text] [Related]  

  • 40. Anti-HIV drug updates--three drugs on the near horizon.
    Proj Inf Perspect; 2003 Jan; (35):4-7. PubMed ID: 12647672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.